Skip to main content
. 2019 Jun 5;4(7):691–695. doi: 10.1001/jamacardio.2019.1647

Figure. Incremental Cost-effectiveness Ratio as a Function of Baseline Cardiovascular Event Rate.

Figure.

Cardiovascular events include myocardial infarction, ischemic stroke, and cardiovascular death. An annual evolocumab list price of $5850 was used. FOURIER indicates the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk trial.